The xenpozyme market research report is one of a series of new reports that provides xenpozyme market statistics, including the xenpozyme industry global market size, regional shares, competitors with the xenpozyme market share, detailed xenpozyme market segments, market trends, and opportunities, and any further data you may need to thrive in the xenpozyme industry. This xenpozyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the increasing adoption of enzyme replacement therapies, rising investments in rare diseases, growing awareness for early diagnosis, increasing adoption of enzyme-based treatments, and growing geriatric population. Major trends in the forecast period include advancements in biotechnology, improved access to genetic testing, innovations in drug delivery systems, the development of cost-effective manufacturing processes, and the development of biomarkers.
The increasing prevalence of genetic disorders is expected to drive the growth of the xenpozyme market in the future. Genetic disorders are conditions caused by abnormalities in an individual's DNA, leading to various health problems. The rising prevalence of these disorders is influenced by factors such as advancements in genetic testing, greater awareness and diagnosis of rare diseases, and improvements in healthcare services. Xenpozyme is used to treat acid sphingomyelinase deficiency (ASMD), a genetic disorder, by providing the missing acid sphingomyelinase enzyme. This enzyme is essential for breaking down sphingomyelin, helping to reduce harmful lipid buildup in cells, alleviate symptoms, and slow the progression of the disease. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity, reported that approximately 11,148 cystic fibrosis patients were registered in 2022, with the number increasing to 11,318 in 2023, reflecting a 1.5% rise in patient registrations year-over-year. As the prevalence of genetic disorders grows, the demand for treatments such as xenpozyme is expected to increase.
The rising demand for personalized medicine is also set to propel the growth of the xenpozyme market. Personalized medicine tailors healthcare treatments to an individual’s genetic profile, lifestyle, and specific health needs, offering the potential for better outcomes. This growing demand is driven by advancements in genetic research, a better understanding of health profiles, improved diagnostic tools, and the promise of more effective, targeted treatments. Xenpozyme works by delivering the missing enzyme needed to break down accumulated substances, providing a personalized treatment approach for patients with MPS I. This therapy is designed to target the enzyme deficiency caused by specific genetic mutations in each patient, offering more customized care. For instance, in February 2024, the Personalized Medicine Coalition, a U.S.-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The increasing demand for personalized medicine is expected to further drive the growth of the xenpozyme market.
A key trend in the xenpozyme market is the development of advanced enzyme replacement therapies to improve treatment outcomes for patients with rare genetic disorders. Enzyme replacement therapy (ERT) involves delivering synthetic or recombinant enzymes to replace those that are deficient or missing in individuals with genetic conditions. This treatment helps restore normal enzyme function and can slow or halt disease progression. For example, in June 2022, Sanofi S.A., a biopharmaceutical company based in France, announced that Xenpozyme (olipudase alfa) was approved by the European Commission as the first and only enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD). This approval followed positive clinical trial results, showing significant improvements in lung function and reductions in the size of the spleen and liver in both pediatric and adult patients.
The key company operating in the xenpozyme market is Sanofi S.A.
North America was the largest region in the xenpozyme market in 2024. The regions covered in xenpozyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the xenpozyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Xenpozyme is an enzyme replacement therapy designed to treat acid sphingomyelinase deficiency (ASMD), including Niemann-Pick disease types A, A/B, and B. It uses recombinant human acid sphingomyelinase (rhASM) to replace the missing enzyme, facilitating the breakdown of sphingomyelin, a lipid that accumulates in various organs.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Xenpozyme is primarily indicated for acid sphingomyelinase deficiency (ASMD) in patients with Niemann-Pick disease types A and B. ASMD with Niemann-Pick disease type A refers to patients who suffer from both ASMD and the severe neurological and organ dysfunctions associated with Niemann-Pick disease type A due to the absence of the enzyme acid sphingomyelinase. The medication is available through various distribution channels, including hospital pharmacies, retail pharmacies, and online platforms, and is used by a wide range of end users, such as adults, geriatrics, and pediatric patients.
The xenpozyme market consists of sales of reconstitution kits and accessories, administration devices, and complementary diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the increasing adoption of enzyme replacement therapies, rising investments in rare diseases, growing awareness for early diagnosis, increasing adoption of enzyme-based treatments, and growing geriatric population. Major trends in the forecast period include advancements in biotechnology, improved access to genetic testing, innovations in drug delivery systems, the development of cost-effective manufacturing processes, and the development of biomarkers.
The increasing prevalence of genetic disorders is expected to drive the growth of the xenpozyme market in the future. Genetic disorders are conditions caused by abnormalities in an individual's DNA, leading to various health problems. The rising prevalence of these disorders is influenced by factors such as advancements in genetic testing, greater awareness and diagnosis of rare diseases, and improvements in healthcare services. Xenpozyme is used to treat acid sphingomyelinase deficiency (ASMD), a genetic disorder, by providing the missing acid sphingomyelinase enzyme. This enzyme is essential for breaking down sphingomyelin, helping to reduce harmful lipid buildup in cells, alleviate symptoms, and slow the progression of the disease. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity, reported that approximately 11,148 cystic fibrosis patients were registered in 2022, with the number increasing to 11,318 in 2023, reflecting a 1.5% rise in patient registrations year-over-year. As the prevalence of genetic disorders grows, the demand for treatments such as xenpozyme is expected to increase.
The rising demand for personalized medicine is also set to propel the growth of the xenpozyme market. Personalized medicine tailors healthcare treatments to an individual’s genetic profile, lifestyle, and specific health needs, offering the potential for better outcomes. This growing demand is driven by advancements in genetic research, a better understanding of health profiles, improved diagnostic tools, and the promise of more effective, targeted treatments. Xenpozyme works by delivering the missing enzyme needed to break down accumulated substances, providing a personalized treatment approach for patients with MPS I. This therapy is designed to target the enzyme deficiency caused by specific genetic mutations in each patient, offering more customized care. For instance, in February 2024, the Personalized Medicine Coalition, a U.S.-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The increasing demand for personalized medicine is expected to further drive the growth of the xenpozyme market.
A key trend in the xenpozyme market is the development of advanced enzyme replacement therapies to improve treatment outcomes for patients with rare genetic disorders. Enzyme replacement therapy (ERT) involves delivering synthetic or recombinant enzymes to replace those that are deficient or missing in individuals with genetic conditions. This treatment helps restore normal enzyme function and can slow or halt disease progression. For example, in June 2022, Sanofi S.A., a biopharmaceutical company based in France, announced that Xenpozyme (olipudase alfa) was approved by the European Commission as the first and only enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD). This approval followed positive clinical trial results, showing significant improvements in lung function and reductions in the size of the spleen and liver in both pediatric and adult patients.
The key company operating in the xenpozyme market is Sanofi S.A.
North America was the largest region in the xenpozyme market in 2024. The regions covered in xenpozyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the xenpozyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Xenpozyme is an enzyme replacement therapy designed to treat acid sphingomyelinase deficiency (ASMD), including Niemann-Pick disease types A, A/B, and B. It uses recombinant human acid sphingomyelinase (rhASM) to replace the missing enzyme, facilitating the breakdown of sphingomyelin, a lipid that accumulates in various organs.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Xenpozyme is primarily indicated for acid sphingomyelinase deficiency (ASMD) in patients with Niemann-Pick disease types A and B. ASMD with Niemann-Pick disease type A refers to patients who suffer from both ASMD and the severe neurological and organ dysfunctions associated with Niemann-Pick disease type A due to the absence of the enzyme acid sphingomyelinase. The medication is available through various distribution channels, including hospital pharmacies, retail pharmacies, and online platforms, and is used by a wide range of end users, such as adults, geriatrics, and pediatric patients.
The xenpozyme market consists of sales of reconstitution kits and accessories, administration devices, and complementary diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Xenpozyme Market Characteristics4. Xenpozyme Market Trends And Strategies5. Xenpozyme Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Xenpozyme Pricing Analysis & Forecasts30. Global Xenpozyme Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Xenpozyme Market32. Recent Developments In The Xenpozyme Market
3. Xenpozyme Market Biologic Drug Characteristics
6. Global Xenpozyme Growth Analysis And Strategic Analysis Framework
8. Xenpozyme Market Segmentation
9. Global Xenpozyme Epidemiology Of Clinical Indications
10. Xenpozyme Market Regional And Country Analysis
11. Asia-Pacific Xenpozyme Market
12. China Xenpozyme Market
13. India Xenpozyme Market
14. Japan Xenpozyme Market
15. Australia Xenpozyme Market
16. South Korea Xenpozyme Market
17. Western Europe Xenpozyme Market
18. UK Xenpozyme Market
19. Germany Xenpozyme Market
20. France Xenpozyme Market
21. Eastern Europe Xenpozyme Market
22. North America Xenpozyme Market
23. USA Xenpozyme Market
24. Canada Xenpozyme Market
25. South America Xenpozyme Market
26. Middle East Xenpozyme Market
27. Africa Xenpozyme Market
28. Xenpozyme Market Competitive Landscape And Company Profiles
29. Global Xenpozyme Market Pipeline Analysis
33. Xenpozyme Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Xenpozyme Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on xenpozyme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for xenpozyme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The xenpozyme market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Acid Sphingomyelinase Deficiency (ASMD) With Niemann-Pick Disease Type A; Acid Sphingomyelinase Deficiency (ASMD) With Niemann-Pick Disease Type B2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-User: Adult; Geriatric; Pediatric
Key Companies Profiled: Sanofi S.A.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A.
